Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resistance by triggering a strong IFN response to induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribas, Antoni, Medina, Theresa, Kirkwood, John M., Zakharia, Yousef, Gonzalez, Rene, Davar, Diwakar, Chmielowski, Bartosz, Campbell, Katie M., Bao, Riyue, Kelley, Heather, Morris, Aaron, Mauro, David, Wooldridge, James E., Luke, Jason J., Weiner, George J., Krieg, Arthur M., Milhem, Mohammed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799774/
https://www.ncbi.nlm.nih.gov/pubmed/34326162
http://dx.doi.org/10.1158/2159-8290.CD-21-0425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799774/
https://www.ncbi.nlm.nih.gov/pubmed/34326162
http://dx.doi.org/10.1158/2159-8290.CD-21-0425

Ejemplares similares